Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

Brian McNamara has a shot at beating his aggressive cancer, but his Aetna subsidiary insurance company doesn't want to pay ...

Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.

Bernstein analyst Florent Cespedes maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...